Bridge Biotherapeutics, Inc. (KOSDAQ: 288330)
South Korea
· Delayed Price · Currency is KRW 4,060.00
-540.00 (-11.74%)
Dec 19, 2024, 3:00 PM KST
Bridge Biotherapeutics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Net Income | -29,766 | -42,321 | -41,700 | -26,278 | -19,232 | 1,325 | Upgrade
|
| Depreciation & Amortization | 1,441 | 1,424 | 1,078 | 381.46 | 357.87 | 451.41 | Upgrade
|
| Loss (Gain) From Sale of Assets | 23 | - | - | - | 1.05 | 22.27 | Upgrade
|
| Loss (Gain) From Sale of Investments | 291.13 | 26.78 | -51.29 | -0.3 | -186.87 | -69.18 | Upgrade
|
| Stock-Based Compensation | 486.43 | 2,645 | 3,546 | 3,292 | 1,412 | 1,408 | Upgrade
|
| Other Operating Activities | 2,993 | 3,073 | -1,644 | -24.62 | 2,722 | -8,386 | Upgrade
|
| Change in Accounts Receivable | -1.08 | -100 | - | 572.25 | -573.23 | - | Upgrade
|
| Change in Inventory | - | - | - | - | 1,933 | -1,933 | Upgrade
|
| Change in Accounts Payable | - | -0.07 | - | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | 591.09 | 3,476 | -1,411 | 929 | 529.83 | -514.45 | Upgrade
|
| Operating Cash Flow | -23,942 | -31,775 | -40,182 | -21,128 | -13,037 | -7,697 | Upgrade
|
| Capital Expenditures | -1.99 | -319.51 | -437.05 | -164.87 | -79.75 | -493.91 | Upgrade
|
| Sale of Property, Plant & Equipment | 5.98 | - | - | - | 0.59 | - | Upgrade
|
| Cash Acquisitions | 0 | -3,787 | - | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | - | -49.25 | -0.81 | -3.8 | - | 2,413 | Upgrade
|
| Investment in Securities | 4,386 | 37,073 | -8,484 | 2,123 | -31,775 | -4,564 | Upgrade
|
| Other Investing Activities | -0 | -0 | 0 | -0 | - | -0 | Upgrade
|
| Investing Cash Flow | 4,390 | 32,917 | -8,922 | 1,955 | -31,854 | -2,644 | Upgrade
|
| Long-Term Debt Repaid | - | -1,024 | -763.67 | -168.14 | -176.04 | -135.77 | Upgrade
|
| Net Debt Issued (Repaid) | -781.93 | -1,024 | -763.67 | -168.14 | -176.04 | -135.77 | Upgrade
|
| Issuance of Common Stock | 23,021 | 3,155 | 828.87 | 6,194 | 2,087 | 40,418 | Upgrade
|
| Other Financing Activities | -41.33 | -12.05 | -0 | - | -51.25 | - | Upgrade
|
| Financing Cash Flow | 22,153 | 5,086 | 48,643 | 6,026 | 1,859 | 67,270 | Upgrade
|
| Foreign Exchange Rate Adjustments | -20.73 | 12.32 | 203.42 | 404.81 | -112.42 | -270.52 | Upgrade
|
| Net Cash Flow | 2,581 | 6,240 | -257.8 | -12,743 | -43,144 | 56,658 | Upgrade
|
| Free Cash Flow | -23,944 | -32,095 | -40,619 | -21,293 | -13,117 | -8,191 | Upgrade
|
| Free Cash Flow Margin | -2217005.21% | -32095.05% | -1343.35% | -1106.61% | -206.90% | -14.05% | Upgrade
|
| Free Cash Flow Per Share | -773.38 | -1301.54 | -1706.25 | -908.42 | -573.78 | -704.16 | Upgrade
|
| Cash Interest Paid | 156.4 | 167.6 | 64.51 | 7.53 | 6.34 | 8.07 | Upgrade
|
| Cash Income Tax Paid | - | 126.74 | 32.69 | -4.88 | -2,662 | 8,591 | Upgrade
|
| Levered Free Cash Flow | -14,433 | -16,679 | -22,289 | -9,435 | -7,027 | -26,181 | Upgrade
|
| Unlevered Free Cash Flow | -14,326 | -16,572 | -22,248 | -9,431 | -7,023 | -24,467 | Upgrade
|
| Change in Net Working Capital | -576.99 | -4,945 | -754.39 | -3,559 | -3,524 | 28,632 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.